Carolyn F. Deacon

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon et al. · Diabetes · 2001 · 877 citations · Full text

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Carolyn F. Deacon, Anders H. Johnsen, Jens J. Holst · The Journal of Clinical Endocrinology & Metabolism · 1995 · 754 citations

Immunology, Glycobiology, Peptide Science +17

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

Carolyn F. Deacon, Michael A. Nauck, M. Toft-Nielsen et al. · Diabetes · 1995 · 716 citations

Diabetes Management, Healthy Subjects, Biochemistry +8

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Carolyn F. Deacon, Michael A. Nauck, Lone Pridal et al. · Diabetes · 1995 · 649 citations

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine¹

Lene Hansen, Carolyn F. Deacon, Cathrine Ørskov et al. · Endocrinology · 1999 · 578 citations · Full text